Brief: Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit For Cytisinicline In Second, Confirmatory Phase 3 Clinical Trial
23/05/2023 11:12
May 23 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES REPORTS STATISTICALLY SIGNIFICANT
SMOKING
CESSATION BENEFIT FOR CYTISINICLINE IN SECOND, CONFIRMATORY
PHASE 3 CLINICAL TRIAL
* ACHIEVE LIFE SCIENCES INC - CYTISINICLINE TREATMENT WELL
TOLERATED WITH LOW RATES OF ADVERSE EVENTS REPORTED
* ACHIEVE LIFE SCIENCES INC - ORCA-3 SHOWED A STATISTICALLY
SIGNIFICANT BENEFIT IN HELPING PEOPLE TO QUIT SMOKING COMPARED
TO PLACEBO
* ACHIEVE LIFE SCIENCES INC - CYTISINICLINE DEMONSTRATED 6X
INCREASE IN ODDS OF CONTINUOUS SMOKING ABSTINENCE AT 6 MONTHS
Source text for Eikon: ID:nGNX31wcJ8
Further company coverage: ACHV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock